Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pharmacogenetics.

C R Wolf1, G Smith

  • 1Imperial Cancer Research Fund, Molecular Pharmacology Unit, Ninewells Hospital and Medical School, Dundee, UK.

British Medical Bulletin
|March 21, 2000
PubMed
Summary
This summary is machine-generated.

Genetic variations significantly impact how individuals respond to medications, leading to adverse drug reactions (ADRs). DNA testing can identify at-risk patients, enabling personalized medicine for safer and more effective drug prescriptions.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Defining the Contribution of CYP1A1 and CYP1A2 to Drug Metabolism Using Humanized CYP1A1/1A2 and Cyp1a1/Cyp1a2 Knockout Mice.

Drug metabolism and disposition: the biological fate of chemicals·2019
Same author

An Extensively Humanized Mouse Model to Predict Pathways of Drug Disposition and Drug/Drug Interactions, and to Facilitate Design of Clinical Trials.

Drug metabolism and disposition: the biological fate of chemicals·2019
Same author

MicroRNA-224 is associated with colorectal cancer progression and response to 5-fluorouracil-based chemotherapy by KRAS-dependent and -independent mechanisms.

British journal of cancer·2015
Same author

Glutathione S-transferase P1 (GSTP1) directly influences platinum drug chemosensitivity in ovarian tumour cell lines.

British journal of cancer·2014
Same author

Immunodetection of proteins by Western blotting.

Methods in molecular biology (Clifton, N.J.)·2012
Same author

Individuality in FGF1 expression significantly influences platinum resistance and progression-free survival in ovarian cancer.

British journal of cancer·2012
Same journal

Human health in relation to visible, functional, and accessible green space: a systematic review and narrative synthesis of the 3 + 30 + 300 guideline.

British medical bulletin·2026
Same journal

Muscle herniae in exercise-induced leg pain: diagnostic pitfalls and the 'repair paradox'.

British medical bulletin·2026
Same journal

Scaffolds and platelet concentrates in bone regenerative medicine: applications, mechanisms, and future approaches.

British medical bulletin·2026
Same journal

Back squat and deadlift fatiguing protocols elicit distinct countermovement jump profiles: phase-specific predictors and soreness responses.

British medical bulletin·2026
Same journal

Enhancing bone healing through osteogenic medium components: biological roles, mechanisms, and clinical applications.

British medical bulletin·2026
Same journal

Moral injury in healthcare workers: causes & interventions.

British medical bulletin·2026
See all related articles

Area of Science:

  • Pharmacogenetics
  • Clinical Pharmacology
  • Genomics

Background:

  • Inter-individual variability in drug response is a significant clinical challenge.
  • Adverse drug reactions (ADRs) contribute to morbidity, mortality, and increased healthcare costs.
  • Genetic factors influencing drug absorption, disposition, metabolism, and excretion underlie much of this variability.

Purpose of the Study:

  • To highlight the genetic basis of drug response variability.
  • To emphasize the role of pharmacogenetic polymorphisms, particularly CYP2D6.
  • To underscore the clinical utility of DNA-based testing for predicting ADR risk.

Main Methods:

  • Review of existing literature on pharmacogenetics and drug metabolism.
  • Focus on cytochrome P450 enzymes, specifically CYP2D6.

Related Experiment Videos

  • Discussion of DNA-based testing for genetic variation identification.

    • Main Results:

    • Genetic polymorphisms in drug-metabolizing enzymes, like CYP2D6, explain a substantial portion of drug response variability.
    • CYP2D6 is a key enzyme, metabolizing 25% of commonly prescribed drugs and being inactive in 6% of Caucasians.
    • DNA testing can identify individuals at risk for ADRs due to specific genetic profiles.

    Conclusions:

    • Understanding the genetic basis of drug response is crucial for personalized medicine.
    • Pharmacogenetic testing, such as for CYP2D6, allows for tailored drug prescriptions.
    • Personalized drug therapy promises significant benefits for patient health and economic efficiency.